PMID-38308608 – Thymosin Alpha-1 Safety and Efficacy in Clinical Trials
Dinetz R et al. "Thymosin Alpha 1: A Comprehensive Review of the Literature on Safety and Efficacy in Clinical Trials," Alternative Therapies in Health and Medicine, 2024;30(3):40-50.
Quick Reference
| Property | Value |
|---|---|
| PMID | 38308608 |
| DOI | — |
| Year | 2024 |
| Journal | Alternative Therapies in Health and Medicine |
| Study Type | Systematic Review |
| Evidence Level | I |
| Sample | 11,000+ subjects across 30+ clinical trials |
| Peptide(s) Studied | Thymosin Alpha-1 |
Key Findings
- Comprehensive analysis of 30+ clinical trials encompassing over 11,000 subjects demonstrates a strong safety profile for thymosin alpha-1
- Efficacy demonstrated across multiple therapeutic domains including hepatitis B/C, cancer adjunct therapy, sepsis, and immunodeficiency
- Cancer-related trials showed improved immune parameters and, in some studies, improved survival when Ta1 was added to chemotherapy or immunotherapy
- Adverse event rates were consistently low and comparable to placebo across studies
- Ta1 showed particular benefit in elderly and immunocompromised populations where immune reconstitution is critical
- The review supports Ta1 as one of the most extensively studied immunomodulatory peptides in clinical medicine
Study Design
Systematic review of published clinical trials evaluating thymosin alpha-1 across all therapeutic indications. Comprehensive literature search covering safety data, efficacy endpoints, and population-specific outcomes. Included trials from multiple countries and regulatory contexts.
Limitations
- Heterogeneity of study designs, dosing regimens, and indications limits direct comparisons
- Many included trials were open-label or non-randomized
- Publication in a complementary medicine journal may limit reach in mainstream oncology literature
- Some included studies were industry-sponsored (SciClone Pharmaceuticals)
Clinical Relevance
This is the most comprehensive safety review of thymosin alpha-1 to date. The 11,000+ patient safety database provides strong reassurance for clinical use, including in cancer patients. The breadth of indications studied reinforces Ta1's role as a versatile immunomodulator. Essential reference for practitioners prescribing Ta1 for immune restoration or cancer adjunct protocols.
Related
#research #systematic-review #evidence-level-I #cancer